IL311666B1 - Use of pyrazolopyrimidine derivatives for the treatment of P13K-related disorders - Google Patents
Use of pyrazolopyrimidine derivatives for the treatment of P13K-related disordersInfo
- Publication number
- IL311666B1 IL311666B1 IL311666A IL31166624A IL311666B1 IL 311666 B1 IL311666 B1 IL 311666B1 IL 311666 A IL311666 A IL 311666A IL 31166624 A IL31166624 A IL 31166624A IL 311666 B1 IL311666 B1 IL 311666B1
- Authority
- IL
- Israel
- Prior art keywords
- mmol
- chloro
- methyl
- ethyl
- pyrazolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771480P | 2013-03-01 | 2013-03-01 | |
| PCT/US2014/019372 WO2014134426A1 (en) | 2013-03-01 | 2014-02-28 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL311666A IL311666A (en) | 2024-05-01 |
| IL311666B1 true IL311666B1 (en) | 2026-05-01 |
Family
ID=50288319
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311666A IL311666B1 (en) | 2013-03-01 | 2014-02-28 | Use of pyrazolopyrimidine derivatives for the treatment of P13K-related disorders |
| IL301180A IL301180A (en) | 2013-03-01 | 2014-02-28 | Use of pyrazolopyrimidine derivatives for the treatment of P13K-related disorders |
| IL240784A IL240784B (en) | 2013-03-01 | 2015-08-24 | Use of pyrazolopyrimidine derivatives for the treatment of p13k-related disorders |
| IL267853A IL267853B (en) | 2013-03-01 | 2019-07-04 | Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders |
| IL274771A IL274771A (en) | 2013-03-01 | 2020-05-19 | Use of pyrazolopyrimidine derivatives for the treatment of PI3Kδ associated disorders |
| IL283943A IL283943B2 (en) | 2013-03-01 | 2021-06-13 | Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301180A IL301180A (en) | 2013-03-01 | 2014-02-28 | Use of pyrazolopyrimidine derivatives for the treatment of P13K-related disorders |
| IL240784A IL240784B (en) | 2013-03-01 | 2015-08-24 | Use of pyrazolopyrimidine derivatives for the treatment of p13k-related disorders |
| IL267853A IL267853B (en) | 2013-03-01 | 2019-07-04 | Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders |
| IL274771A IL274771A (en) | 2013-03-01 | 2020-05-19 | Use of pyrazolopyrimidine derivatives for the treatment of PI3Kδ associated disorders |
| IL283943A IL283943B2 (en) | 2013-03-01 | 2021-06-13 | Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders |
Country Status (32)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2448938B9 (en) | 2009-06-29 | 2015-06-10 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| MX389479B (es) | 2011-09-02 | 2025-03-20 | Incyte Holdings Corp | Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k) |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| TWI662030B (zh) | 2013-01-15 | 2019-06-11 | 英塞特控股公司 | 適用作ｐｉｍ激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物 |
| TWI736135B (zh) | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| CA3158254C (en) | 2014-04-08 | 2024-05-21 | Incyte Corporation | Treatment of b-cell malignancies by a combination jak and pi3k inhibitors |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| SG10201912302VA (en) | 2015-02-27 | 2020-02-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| ES2995198T3 (en) | 2016-01-05 | 2025-02-07 | Incyte Corp | Pyridine compounds as pi3k-gamma inhibitors |
| WO2017172368A1 (en) | 2016-03-31 | 2017-10-05 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| TW201803871A (zh) | 2016-06-24 | 2018-02-01 | 英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 |
| NZ761680A (en) * | 2017-09-08 | 2023-03-31 | Beigene Ltd | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors |
| KR102717072B1 (ko) | 2017-10-18 | 2024-10-15 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| UA124694C2 (uk) * | 2018-01-10 | 2021-10-27 | Ідорсія Фармасьютікалз Лтд | 2,4,6,7-ТЕТРАГІДРОПІРАЗОЛО[4,3-d]ПІРИМІДИН-5-ОНОВІ ПОХІДНІ ТА СПОРІДНЕНІ СПОЛУКИ ЯК МОДУЛЯТОРИ РЕЦЕПТОРА C5A ДЛЯ ЛІКУВАННЯ ВАСКУЛІТУ ТА ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| IL278889B2 (en) | 2018-06-01 | 2025-11-01 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| TWI727392B (zh) * | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| CN110833552A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途 |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| US20220241411A1 (en) | 2020-11-30 | 2022-08-04 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| CN112808550B (zh) * | 2020-12-28 | 2021-10-01 | 青岛理工大学 | 用于海洋工程的劣化免疫仿生防护界面及制备方法 |
| US20230190755A1 (en) | 2021-12-16 | 2023-06-22 | Incyte Corporation | Topical formulations of PI3K-delta inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013033569A1 (en) * | 2011-09-02 | 2013-03-07 | Incyte Corporation | Heterocyclylamines as pi3k inhibitors |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| CN100391958C (zh) | 2001-09-19 | 2008-06-04 | 安万特医药股份有限公司 | 化合物 |
| PT1441737E (pt) | 2001-10-30 | 2006-12-29 | Dana Farber Cancer Inst Inc | Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3 |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| MXPA06014247A (es) | 2004-06-10 | 2007-03-12 | Irm Llc | Compuestos y composiciones como inhibidores de la proteina quinasa. |
| RU2007123675A (ru) | 2004-11-24 | 2008-12-27 | Новартис АГ (CH) | Комбинации ингибиторов jak |
| NZ592968A (en) | 2006-01-17 | 2012-08-31 | Vertex Pharma | Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2 |
| WO2009026701A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Sirtuin inhibitors |
| WO2009157880A1 (en) | 2008-06-27 | 2009-12-30 | S*Bio Pte Ltd | Pyrazine substituted purines |
| AR073651A1 (es) | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| WO2010036380A1 (en) * | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| US20120046333A1 (en) | 2009-04-09 | 2012-02-23 | Oncothyreon Incorporated | Methods and Compositions of PI-3 Kinase Inhibitors for Treating Fibrosis |
| EP2448938B9 (en) | 2009-06-29 | 2015-06-10 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
| AR077974A1 (es) | 2009-08-28 | 2011-10-05 | Takeda Pharmaceutical | Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| WO2011075630A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| JP5961187B2 (ja) | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン |
| USRE47009E1 (en) | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| TWI736135B (zh) * | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| US10077277B2 (en) * | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| SG10201912302VA (en) * | 2015-02-27 | 2020-02-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| IL278889B2 (en) | 2018-06-01 | 2025-11-01 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| US11161838B2 (en) * | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
-
2014
- 2014-02-27 TW TW109104878A patent/TWI736135B/zh active
- 2014-02-27 TW TW103106906A patent/TWI657090B/zh active
- 2014-02-27 TW TW112117019A patent/TWI841376B/zh active
- 2014-02-27 TW TW110124946A patent/TW202214254A/zh unknown
- 2014-02-27 TW TW108100664A patent/TWI687220B/zh active
- 2014-02-28 CN CN201810796220.8A patent/CN109010343A/zh active Pending
- 2014-02-28 AU AU2014223257A patent/AU2014223257B2/en active Active
- 2014-02-28 US US14/193,481 patent/US9932341B2/en active Active
- 2014-02-28 SM SM20200043T patent/SMT202000043T1/it unknown
- 2014-02-28 EP EP14710739.5A patent/EP2961410B1/en active Active
- 2014-02-28 DK DK14710739.5T patent/DK2961410T3/da active
- 2014-02-28 EA EA201591612A patent/EA201591612A1/ru unknown
- 2014-02-28 PE PE2015001833A patent/PE20151996A1/es not_active Application Discontinuation
- 2014-02-28 WO PCT/US2014/019372 patent/WO2014134426A1/en not_active Ceased
- 2014-02-28 IL IL311666A patent/IL311666B1/en unknown
- 2014-02-28 SG SG10201912275YA patent/SG10201912275YA/en unknown
- 2014-02-28 CA CA2901993A patent/CA2901993C/en active Active
- 2014-02-28 CN CN201480021187.1A patent/CN105120871B/zh active Active
- 2014-02-28 MX MX2015011273A patent/MX367713B/es active IP Right Grant
- 2014-02-28 PT PT147107395T patent/PT2961410T/pt unknown
- 2014-02-28 IL IL301180A patent/IL301180A/en unknown
- 2014-02-28 UA UAA201509435A patent/UA119641C2/uk unknown
- 2014-02-28 JP JP2015560346A patent/JP6545106B2/ja active Active
- 2014-02-28 HU HUE14710739A patent/HUE047719T2/hu unknown
- 2014-02-28 EP EP19208523.1A patent/EP3632442B1/en active Active
- 2014-02-28 EP EP23161858.8A patent/EP4233869A3/en active Pending
- 2014-02-28 EA EA202192151A patent/EA202192151A1/ru unknown
- 2014-02-28 SI SI201431449T patent/SI2961410T1/sl unknown
- 2014-02-28 PL PL14710739T patent/PL2961410T3/pl unknown
- 2014-02-28 ES ES19208523T patent/ES2945212T3/es active Active
- 2014-02-28 KR KR1020247033698A patent/KR20240152422A/ko active Pending
- 2014-02-28 KR KR1020227035039A patent/KR102586858B1/ko active Active
- 2014-02-28 MY MYPI2015002108A patent/MY177875A/en unknown
- 2014-02-28 KR KR1020217027697A patent/KR102454308B1/ko active Active
- 2014-02-28 LT LTEP14710739.5T patent/LT2961410T/lt unknown
- 2014-02-28 SG SG10201707130UA patent/SG10201707130UA/en unknown
- 2014-02-28 AR ARP140100679A patent/AR094964A1/es unknown
- 2014-02-28 PH PH1/2021/552233A patent/PH12021552233A1/en unknown
- 2014-02-28 HR HRP20200263TT patent/HRP20200263T1/hr unknown
- 2014-02-28 KR KR1020157027010A patent/KR102298150B1/ko active Active
- 2014-02-28 SG SG11201506654UA patent/SG11201506654UA/en unknown
- 2014-02-28 BR BR112015020941A patent/BR112015020941A2/pt not_active Application Discontinuation
- 2014-02-28 KR KR1020237033761A patent/KR102717616B1/ko active Active
- 2014-02-28 RS RS20200176A patent/RS59958B1/sr unknown
- 2014-02-28 ES ES14710739T patent/ES2774436T3/es active Active
-
2015
- 2015-08-24 IL IL240784A patent/IL240784B/en not_active IP Right Cessation
- 2015-08-28 MX MX2019010422A patent/MX2019010422A/es unknown
- 2015-08-31 CL CL2015002442A patent/CL2015002442A1/es unknown
- 2015-09-01 PH PH12015501920A patent/PH12015501920A1/en unknown
- 2015-09-10 CR CR20150472A patent/CR20150472A/es unknown
-
2018
- 2018-03-02 US US15/910,708 patent/US20190040067A1/en not_active Abandoned
- 2018-11-14 AU AU2018264053A patent/AU2018264053B2/en active Active
-
2019
- 2019-04-25 JP JP2019084393A patent/JP6776399B2/ja active Active
- 2019-06-11 PH PH12019501321A patent/PH12019501321B1/en unknown
- 2019-07-04 IL IL267853A patent/IL267853B/en active IP Right Grant
-
2020
- 2020-02-26 CY CY20201100177T patent/CY1122712T1/el unknown
- 2020-05-19 IL IL274771A patent/IL274771A/en unknown
- 2020-07-31 AU AU2020210278A patent/AU2020210278B2/en active Active
- 2020-10-07 JP JP2020169551A patent/JP7189185B2/ja active Active
-
2021
- 2021-06-13 IL IL283943A patent/IL283943B2/en unknown
- 2021-06-30 US US17/364,695 patent/US20210332059A1/en not_active Abandoned
- 2021-06-30 US US17/364,585 patent/US20220119393A1/en not_active Abandoned
- 2021-06-30 US US17/364,551 patent/US12152033B2/en active Active
-
2022
- 2022-08-16 AU AU2022218495A patent/AU2022218495B2/en active Active
- 2022-12-01 JP JP2022192954A patent/JP7556010B2/ja active Active
-
2024
- 2024-09-11 JP JP2024157116A patent/JP2025003975A/ja active Pending
- 2024-10-24 US US18/926,010 patent/US20250289823A1/en active Pending
- 2024-12-23 AU AU2024287194A patent/AU2024287194A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013033569A1 (en) * | 2011-09-02 | 2013-03-07 | Incyte Corporation | Heterocyclylamines as pi3k inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283943B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders | |
| IL268094B (en) | History of heterocyclic compounds for use in the treatment of lung cancer | |
| PL3811943T3 (pl) | Związek do stosowania w leczeniu zaburzeń oczu | |
| IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| IL244014A0 (en) | Combined therapy for the treatment of glioblastoma | |
| PL3007694T3 (pl) | Pochodne pirazolopirydynowe do zastosowania w leczeniu nowotworu pęcherza moczowego | |
| PL3033086T3 (pl) | Terapia skojarzona do leczenia nowotworów złośliwych | |
| IL241553B (en) | Secondary vaccine particles for the treatment of inflammation | |
| SG11201507615SA (en) | 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders | |
| PL2838539T3 (pl) | Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych | |
| PL3062790T3 (pl) | Połączenia farmaceutyczne do leczenia raka | |
| ZA201507724B (en) | The treatment of inflammatory disorders | |
| EP3089984A4 (en) | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | |
| SI2855487T1 (sl) | Spojine za zdravljenje ishemično-reperfuzijsko-povezanih bolezni | |
| HK40027828B (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| ZA201508530B (en) | Pyrazolopyridine derivatives for use in the treatment of bladder cancer | |
| EP2970118A4 (en) | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| AP2015008751A0 (en) | 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders | |
| GB201303721D0 (en) | Compositions for treatment of sleep disorders |